197 related articles for article (PubMed ID: 16188955)
1. Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism.
von Weymarn LB; Brown KM; Murphy SE
J Pharmacol Exp Ther; 2006 Jan; 316(1):295-303. PubMed ID: 16188955
[TBL] [Abstract][Full Text] [Related]
2. CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine Δ5'(1')iminium ion.
von Weymarn LB; Retzlaff C; Murphy SE
J Pharmacol Exp Ther; 2012 Nov; 343(2):307-15. PubMed ID: 22869927
[TBL] [Abstract][Full Text] [Related]
3. Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes.
Murphy SE; Raulinaitis V; Brown KM
Drug Metab Dispos; 2005 Aug; 33(8):1166-73. PubMed ID: 15860657
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of nicotine and cotinine by human cytochrome P450 2A13.
Bao Z; He XY; Ding X; Prabhu S; Hong JY
Drug Metab Dispos; 2005 Feb; 33(2):258-61. PubMed ID: 15528319
[TBL] [Abstract][Full Text] [Related]
5. Inhibition and inactivation of cytochrome P450 2A6 and cytochrome P450 2A13 by menthofuran, β-nicotyrine and menthol.
Kramlinger VM; von Weymarn LB; Murphy SE
Chem Biol Interact; 2012 May; 197(2-3):87-92. PubMed ID: 22486895
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of neurotransmitters and steroids on human CYP2A6.
Higashi E; Nakajima M; Katoh M; Tokudome S; Yokoi T
Drug Metab Dispos; 2007 Apr; 35(4):508-14. PubMed ID: 17237153
[TBL] [Abstract][Full Text] [Related]
7. Identification of critical amino acid residues of human CYP2A13 for the metabolic activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen.
He XY; Shen J; Ding X; Lu AY; Hong JY
Drug Metab Dispos; 2004 Dec; 32(12):1516-21. PubMed ID: 15333516
[TBL] [Abstract][Full Text] [Related]
8. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Malaiyandi V; Goodz SD; Sellers EM; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
[TBL] [Abstract][Full Text] [Related]
9. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice.
Siu EC; Tyndale RF
J Pharmacol Exp Ther; 2008 Mar; 324(3):992-9. PubMed ID: 18065502
[TBL] [Abstract][Full Text] [Related]
10. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Su T; Bao Z; Zhang QY; Smith TJ; Hong JY; Ding X
Cancer Res; 2000 Sep; 60(18):5074-9. PubMed ID: 11016631
[TBL] [Abstract][Full Text] [Related]
11. Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism.
Murphy SE; Johnson LM; Pullo DA
Chem Res Toxicol; 1999 Jul; 12(7):639-45. PubMed ID: 10409404
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based inactivation of cytochrome P450 2A6 and 2A13 by Rhinacanthus nasutus constituents.
Pouyfung P; Prasopthum A; Sarapusit S; Srisook E; Rongnoparut P
Drug Metab Pharmacokinet; 2014; 29(1):75-82. PubMed ID: 23903410
[TBL] [Abstract][Full Text] [Related]
13. CYP2A13: variable expression and role in human lung microsomal metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone.
Zhang X; D'Agostino J; Wu H; Zhang QY; von Weymarn L; Murphy SE; Ding X
J Pharmacol Exp Ther; 2007 Nov; 323(2):570-8. PubMed ID: 17671098
[TBL] [Abstract][Full Text] [Related]
14. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6.
Dicke KE; Skrlin SM; Murphy SE
Drug Metab Dispos; 2005 Dec; 33(12):1760-4. PubMed ID: 16174803
[TBL] [Abstract][Full Text] [Related]
15. Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK.
Wang H; Tan W; Hao B; Miao X; Zhou G; He F; Lin D
Cancer Res; 2003 Nov; 63(22):8057-61. PubMed ID: 14633739
[TBL] [Abstract][Full Text] [Related]
16. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes.
DeVore NM; Scott EE
J Biol Chem; 2012 Aug; 287(32):26576-85. PubMed ID: 22700965
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based inactivation of cytochrome P450 2A6 by decursinol angelate isolated from Angelica Gigas.
Yoo HH; Lee MW; Kim YC; Yun CH; Kim DH
Drug Metab Dispos; 2007 Oct; 35(10):1759-65. PubMed ID: 17620343
[TBL] [Abstract][Full Text] [Related]
18. Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human peripheral lung microsomes.
Brown PJ; Bedard LL; Reid KR; Petsikas D; Massey TE
Drug Metab Dispos; 2007 Nov; 35(11):2086-94. PubMed ID: 17717079
[TBL] [Abstract][Full Text] [Related]
19. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.
Tyndale RF; Sellers EM
Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):548-52. PubMed ID: 11259349
[TBL] [Abstract][Full Text] [Related]
20. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
Dempsey D; Tutka P; Jacob P; Allen F; Schoedel K; Tyndale RF; Benowitz NL
Clin Pharmacol Ther; 2004 Jul; 76(1):64-72. PubMed ID: 15229465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
